Comparison of the Clinical Efficacy of Ampicillin/Sulbactam and Cefoperazone/Sulbactam Against Multidrug Resistant Acinetobacter Baumannii Infections in Critically Ill Patients

Recruiting now · Not applicable

Conditions studied: Acinetobacter Baumannii Infection

In brief

To compare the clinical effectiveness of two different sulbactam-based regimens (ampicillin-sulbactam versus cefoperazone-sulbactam) in the treatment of Acinetobacter baumannii infections in critically ill patients.

Key facts

Study ID

NCT07118384

Run by

Cairo University

People needed

50

Starts

2025-05-01

Expected to finish

2026-01-01

Last updated by the study team

2025-08-12

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Inclusion criteria:
• Age ≥21 years old.
• Patient with signs and symptoms of sepsis.
• positive culture Carbapenem-resistant Acinetobacter baumannii (CRAB).

You may not qualify if…

• Exclusion criteria:
• Empirical sulbactam-based therapy against Gram-negative bacteria
• History of hypersensitivity reactions to ampicillin-sulbactam/cefoperazone-sulbactam

Where it is running

• Cairo university hospitals kasr alainy — Cairo, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.